Evidence map›Paper›PMID 30133094›Full record

ArticleAngewandte Chemie (International ed. in English)2018

Synthesis, Structural Reassignment, and Antibacterial Evaluation of 2,18-Seco-Lankacidinol B.

Yanmin Yao, Lingchao Cai, Ian B Seiple

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Modular Approaches to Lankacidin Antibiotics.Journal of the American Chemical Society · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yanmin YaoDepartment of Pharmaceutical Chemistry and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, 94158, USA.
Lingchao CaiDepartment of Pharmaceutical Chemistry and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, 94158, USA.
Ian B SeipleDepartment of Pharmaceutical Chemistry and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, 94158, USA.ORCID 0000-0002-8732-1362

Funding

Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Platforms for the Synthesis of Bacterial Protein Synthesis InhibitorsR35GM128656 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEIPLE, IAN BASS · 2018 to 2022
$2.1M
NCATS NIH HHS UL1 TR001872NIGMS NIH HHS R35 GM128656
6 · The paper itself

Abstract

Lankacidins are a group of polyketide natural products with activity against several strains of Gram-positive bacteria. We developed a route to stereochemically diverse variants of 2,18-seco-lankacidinol B and found that the stereochemical assignment at C4 requires revision. This has interesting implications for the biosynthesis of natural products of the lankacidin class, all of which possessed uniform stereochemistry prior to this finding. We have evaluated 2,18-seco-lankacidinol B and three stereochemical derivatives against a panel of pathogenic Gram-positive and Gram-negative bacteria.

Indexed as

Anti-Bacterial AgentsCarbon-13 Magnetic Resonance SpectroscopyGram-Negative BacteriaGram-Positive BacteriaMacrolidesMicrobial Sensitivity TestsMolecular StructureProton Magnetic Resonance Spectroscopy2,18-seco-lankacidinol BAnti-Bacterial AgentsMacrolidesantibioticsbiosynthesisnatural productsstructural reassignmenttotal synthesis

Identifiers

PMID30133094
PMCPMC6494672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.